Heterogeneity within and between physician-diagnosed asthma and/or COPD: NOVELTY cohort.

Helen K Reddel, Jørgen Vestbo, Alvar Agustí, Gary P Anderson, Aruna T Bansal, Richard Beasley, Elisabeth H Bel, Christer Janson, Barry Make, Ian D Pavord, David Price, Eleni Rapsomaniki, Niklas Karlsson, Donna K Finch, Javier Nuevo, Alex de Giorgio-Miller, Marianna Alacqua, Rod Hughes, Hana Müllerová, Maria Gerhardsson de Verdier

Journal: The European respiratory journal 2021;58(3):2003927

PMID: 33632799

Abstract

BACKGROUND

Studies of asthma and chronic obstructive pulmonary disease (COPD) typically focus on these diagnoses separately, limiting understanding of disease mechanisms and treatment options. NOVELTY is a global, 3-year, prospective observational study of patients with asthma and/or COPD from real-world clinical practice. We investigated heterogeneity and overlap by diagnosis and severity in this cohort.

METHODS

Patients with physician-assigned asthma, COPD or both (asthma+COPD) were enrolled, and stratified by diagnosis and severity. Baseline characteristics were reported descriptively by physician-assigned diagnosis and/or severity. Factors associated with physician-assessed severity were evaluated using ordinal logistic regression analysis.

RESULTS

Of 11 243 patients, 5940 (52.8%) had physician-assigned asthma, 1396 (12.4%) had asthma+COPD and 3907 (34.8%) had COPD; almost half were from primary care. Symptoms, health-related quality of life and spirometry showed substantial heterogeneity and overlap between asthma, asthma+COPD and COPD, with 23%, 62% and 64% of patients, respectively, having a ratio of post-bronchodilator forced expiratory volume in 1 s to forced vital capacity below the lower limit of normal. Symptoms and exacerbations increased with greater physician-assessed severity and were higher in asthma+COPD. However, 24.3% with mild asthma and 20.4% with mild COPD had experienced ≥1 exacerbation in the past 12 months. Medication records suggested both under-treatment and over-treatment relative to severity. Blood eosinophil counts varied little across diagnosis and severity groups, but blood neutrophil counts increased with severity across all diagnoses.

CONCLUSION

This analysis demonstrates marked heterogeneity within, and overlap between, physician-assigned diagnosis and severity groups in patients with asthma and/or COPD. Current diagnostic and severity classifications in clinical practice poorly differentiate between clinical phenotypes that may have specific risks and treatment implications.

Copyright ©The authors 2021.

Address: The Woolcock Institute of Medical Research and the University of Sydney, Sydney, Australia [email protected].; University of Manchester and Manchester University NHS Foundation Trust, Manchester, UK.; Respiratory Institute, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERES, Barcelona, Spain.; Lung Health Research Centre, Dept of Pharmacology and Therapeutics, University of Melbourne, Melbourne, Australia.; Acclarogen, Cambridge, UK.; Medical Research Institute of New Zealand, Wellington, New Zealand.; Amsterdam UMC, Location AMC, University of Amsterdam, Amsterdam, The Netherlands.; Dept of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden.; National Jewish Health and University of Colorado Denver, Denver, CO, USA.; Respiratory Medicine Unit and Oxford Respiratory NIHR BRC, Nuffield Dept of Medicine, University of Oxford, Oxford, UK.; Observational and Pragmatic Research Institute, Singapore.; Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK.; BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.; Patient Centered Science, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden.; Early Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.; Medical Dept, BioPharmaceuticals Medical, AstraZeneca, Madrid, Spain.; Medical and Scientific Affairs, BioPharmaceuticals Medical, AstraZeneca, Luton, UK.; Respiratory and Immunology, Medical and Payer Evidence Strategy, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.; External Scientific Engagement, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.; Respiratory Medical Evidence Strategy, BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.